Farmak International sp. z o.o.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2003-05-07
Share capital
26,872,500.00 PLN
Average employment (FTE)
114 (2025)
Activity description

Farmak International operates in the pharmaceutical sector, offering prescription medicines, over-the-counter medicines, dietary supplements and medical devices. Its communicated medicinal products include Dutilox and Levosimendan Farmak, and the company also participates in medical and pharmaceutical conferences.

Registered address
ul. Koszykowa 65, 00-667 Warszawa, Poland
Email
Phone
Electronic delivery address
AE:PL-96957-39254-VVRTU-32

Financials

Revenue history (in m)

From the notes

Profit allocationLoss covered
Loans and borrowings$2,048,521
Capital expenditure$548,985
Planned capital expenditure (next year)$77,875
Foreign sales64.62% of revenue ($62,806,880)
Revenue structureSprzedaż produktów

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 153 days for 2021). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202415/07/2025
  • 202324/09/2024
  • 202227/09/2023
  • 202115/12/2022
  • 202013/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing745 / 24,649
Top 3.0%
City · Warszawa636 / 56,955
Top 1.1%
Voivodeship · Mazowieckie814 / 77,195
Top 1.1%
Country · Poland2,251 / 298,026
Top <1%

Results vs industry

Revenue
This companyUSD 101.65mMedianUSD 165.97kAverageUSD 2.30m
Net profit
This companyUSD 5.87mMedianUSD 1.32kAverageUSD 109.80k
Operating costs
This companyUSD 92.61mMedianUSD 201.81kAverageUSD 2.10m
Assets
This companyUSD 50.33mMedianUSD 118.27kAverageUSD 1.54m

Websites

The sites target these markets: United Kingdom.

  • farmakinternational.plFarmak International Sp. z o.o.
    JoomlaGoogle AnalyticsGoogle Tag ManagerLiteSpeed
  • pikopil.plStrona główna
    JoomlaGoogle AnalyticsGoogle Tag ManagerLiteSpeed

Public procurement

Farmak International has been a party to 2 cases before the National Appeal Chamber (since 2024).

Subject of disputeOutcome
Order
–
Judgment
Upheld

Trademarks

The company holds 109 active trademarks registered with the Polish Patent Office. 2 applications are pending. 20 marks have expired or were not registered. The first mark was filed in 2005.

MarkNumberClassesStatusProtected until
ASIL (word)Z.5945325Protected Nov 28, 2035
SIDAB (word)Z.5816365Protected Mar 13, 2035
MIGRAMOL (word)Z.5816345Protected Mar 13, 2035
Septogard plus Z.5816285Protected Mar 13, 2035
REGUBLO (word)Z.5816335Protected Mar 13, 2035
MarkProtected until
ASIL (word)Nov 28, 2035
SIDAB (word)Mar 13, 2035
MIGRAMOL (word)Mar 13, 2035
Septogard plus Mar 13, 2035
REGUBLO (word)Mar 13, 2035

Authorized Representatives

Magdalena Anita Marzec age 52 – President of the Management Board
Katarzyna Klimek age 40 – Vice-Prezes Zarządu
Michał Żebrowski age 40 – Attorney-in-fact (joint)

Manner of representation

If the management board is a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Supervisory board

Paulina Beata Romaniszyn age 52 – Supervisory Board Member
Viktor Kostiuk – Supervisory Board Member
Volodymyr Zadorozhnyi – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
Farmak Group Limited
53,745$7,258,914.10100%

Beneficial owners

Person

Sanctions and PEP

Sanctions

No matches (EU, UN, US, UK, MSWiA, World Bank)

PEP

No matches

Bank accounts

Registered as a VAT taxpayer on 2003-12-31.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 166.2K

MSiG notices

Publication dateEvent
Feb 4, 2025Merger plan

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$897.5K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Adamed Pharma S.A.
Aflofarm Farmacja Polska sp. z o.o.
Biofarm sp. z o.o.
Zentiva Polska sp. z o.o.
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.
Synoptis Pharma sp. z o.o.
Polfarmex S.A.
SUN-Farm sp. z o.o.
Tactica Pharmaceuticals sp. z o.o.
Aristo Pharma sp. z o.o.

Change history

DateEvent
2025-04-01Share capital increase
2025-04-01Name change
2017-03-16Address change
2015-07-23PKD change
2013-02-21Share capital increase

FAQ

Last updated: 2026-10-07